Adverse Pr

Adverse Pregnancy Outcomes Contribute to Cardiovascular Risk for Overweight Women

Complications during pregnancy, such as gestational diabetes and newly developed high blood pressure, may contribute to cardiovascular disease later in life, according to research published in the Journal of the American College of Cardiology.  The findings suggest that prioritising weight management earlier in the life course before pregnancy may promote maternal and midlife cardiovascular health. “Understanding the connection between adverse pregnancy outcomes and cardiovascular disease is important in the development of effective preventative strategies and determining the best timing...

Silent pandemic: AMR behind 3 million child deaths in 2022

More than 3 million children globally died in 2022 due to infections associated with antimicrobial resistance (AMR), according to new data from a landmark study presented at ESCMID Global 2025.  The study highlights the growing threat of AMR to pa...

Fast action, better outcomes: WHO targets meningitis with first-ever global guidelines

The World Health Organization (WHO) has released its first-ever global guidelines for the diagnosis, treatment and care of meningitis, offering a crucial clinical resource for healthcare professionals to reduce deaths and disability caused by the dis...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
Why lipopr
6:33

Why lipoprotein(a) matters for clinical decisions and patient risk?

Presenter: Martha Gulati
Cardiology
ACC 2025
Chief Medi
9:42

Chief Medical Officer's take on ACC.25

Presenter: Richard J. Kovacs
Cardiology
ACC 2025
Arrhythmia
14:34

Arrhythmia Management: Updates From Recent Practice Guidance Documents

Presenter: John K. Triedman
Cardiology
ACC 2025
Chronic Co
11:29

Chronic Coronary Disease Management in 2025: What's New in the Guidelines?

Presenter: Benjamin H. Freed
Cardiology
ACC 2025
Highlights
16:24

Highlights of ACC.25

Presenter: B. Hadley Wilson
Cardiology
ACC 2025
From Evide
2:49

From Evidence Generation to Implementation: Tackling Unmet Need in ASCVD

Presenter: Ankeet S. Bhatt
Cardiology
ACC 2025
ALIGN-AR r
9:10

ALIGN-AR reports positive outcomes with dedicated TAVI device for aortic regurgitation

Presenter: Raj Makkar
Cardiology
ACC 2025
Shifting t
6:29

Shifting the Paradigm: Lipoprotein(a) in Cardiovascular Disease

Presenter: Alan Brown
Cardiology
ACC 2025
Lorundrost
9:37

Lorundrostat shows continued promise against uncontrolled hypertension

Presenter: Luke Laffin
Cardiology
ACC 2025
Nurse-led
6:19

Nurse-led behavior changes after heart attack cut subsequent event risk by 30%

Presenter: Giulia Magnani
Cardiology
ACC 2025
Dapagliflo
5:42

Dapagliflozin Reduced LVMI in Patients with CKD : DECODE-CKD

Presenter: Tor Biering-Sørensen
Cardiology
ACC 2025
Lifetime B
3:04

Lifetime Benefit by Control of Modifiable Risk Factors

Presenter: Christina Magnussen
Cardiology
ACC 2025
Discussion
8:17

Discussion on Optimizing Hypertension Management: We Need New Treatment and Interventions

Presenter: Paul Whelton
Cardiology
ACC 2025
WARRIOR st
14:00

WARRIOR study: Intensive medical therapy does not help or harm women with chest pain

Cardiology
ACC 2025
Low-dose a
3:32

Low-dose apixiban comparable to full dose for preventing VTE recurrence in patients with cancer

Presenter: Isabelle Mahé
Cardiology
ACC 2025
Research s
4:20

Research shows clopidogrel as better long-term therapy than aspirin after PCI - report from ACC.25

Presenter: Joo-Yong Hahn
Cardiology
ACC 2025
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The import
11:22

The importance of the anterior interface in eye surgery

Presenter: Marie-José Tassignon
Internal Medicine
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology